Organicell Regenerative Medicine, Inc. (OCEL) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Organicell Regenerative Medicine, Inc. (OCEL) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Organicell Regenerative Medicine, Inc. (OCEL) Resumen de Asistencia Médica y Tuberías
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company developing biological therapeutics, primarily Zofin, for degenerative diseases. Zofin, derived from perinatal sources, is currently in Phase I/II clinical trials for COVID-19, positioning Organicell within the regenerative medicine sector alongside competitors like AMHV and ATHJF.
Tesis de Inversión
Organicell Regenerative Medicine, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is approximately $0.02 billion, with a negative P/E ratio of -3.75, reflecting its current lack of profitability. The primary value driver is the potential success of Zofin in clinical trials, particularly its Phase I/II trial for COVID-19. Upcoming data releases from these trials will be critical catalysts. A gross margin of 81.6% indicates strong potential profitability if Zofin gains regulatory approval and achieves commercial success. However, the company's negative profit margin of -92.3% highlights the significant expenses associated with research and development. The stock's beta of 1.36 suggests higher volatility compared to the overall market. The company's success hinges on navigating the regulatory landscape and securing partnerships for manufacturing and distribution.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.02 billion reflects its small size and early stage of development.
- Negative P/E ratio of -3.75 indicates the company is currently unprofitable.
- Gross margin of 81.6% suggests strong potential profitability if products are successfully commercialized.
- Profit margin of -92.3% highlights significant R&D expenses and lack of revenue from product sales.
- Beta of 1.36 indicates higher volatility compared to the market average.
Competidores y Pares
Fortalezas
- Proprietary technology in perinatal-derived biologics.
- Zofin in Phase I/II clinical trials for COVID-19.
- Research collaborations with reputable institutions.
- High gross margin potential (81.6%).
Debilidades
- Negative profit margin (-92.3%).
- Limited revenue generation.
- Reliance on the success of Zofin.
- Small market capitalization.
Catalizadores
- Upcoming: Data readout from Phase I/II clinical trials for Zofin in COVID-19 treatment expected in late 2026.
- Ongoing: Potential for securing government grants and funding for research and development.
- Ongoing: Progress in expanding Zofin's applications to other degenerative diseases.
- Ongoing: Strategic partnership discussions with larger pharmaceutical companies.
Riesgos
- Potential: Failure of Zofin in clinical trials.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from established pharmaceutical companies with greater resources.
- Ongoing: Financial constraints and the need for additional funding to support operations.
- Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.
Oportunidades de crecimiento
- Zofin Clinical Trial Success: The successful completion of Phase I/II clinical trials for Zofin in treating COVID-19 could lead to regulatory approval and commercialization. The global market for COVID-19 therapeutics remains significant, although evolving with vaccination efforts. Positive trial results would significantly increase Organicell's valuation and attract potential partnerships. Timeline: Data readout expected in late 2026.
- Expansion of Zofin to Other Indications: Organicell can explore Zofin's potential in treating other degenerative diseases beyond COVID-19. The regenerative medicine market for conditions like osteoarthritis, Alzheimer's disease, and cardiovascular diseases is substantial. Successful preclinical and clinical studies in these areas could broaden Zofin's market reach. Timeline: Preclinical studies ongoing, with potential clinical trials starting in 2027.
- Strategic Partnerships and Licensing Agreements: Partnering with larger pharmaceutical companies for manufacturing, distribution, and commercialization of Zofin can accelerate its market penetration. Licensing agreements in specific geographic regions or for specific indications can generate revenue and reduce financial risk. Timeline: Ongoing discussions, with potential agreements in 2026-2027.
- Government Grants and Funding: Securing government grants and funding for research and development can reduce Organicell's financial burden and support its clinical programs. Government agencies and foundations are increasingly investing in regenerative medicine research. Timeline: Ongoing applications, with potential awards in 2026.
- Development of New Biologic Therapeutics: Expanding the pipeline with new biologic therapeutics targeting other degenerative diseases can diversify Organicell's product portfolio and reduce its reliance on Zofin. This requires investment in research and development and the acquisition of new technologies or intellectual property. Timeline: Research and development ongoing, with potential new product candidates in 2028.
Oportunidades
- Expansion of Zofin to other degenerative diseases.
- Strategic partnerships for manufacturing and distribution.
- Government grants and funding for research.
- Development of new biologic therapeutics.
Amenazas
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Financial constraints and need for additional funding.
Ventajas competitivas
- Proprietary technology in deriving and manufacturing Zofin from perinatal sources.
- Intellectual property protection for Zofin and its therapeutic applications.
- Established research collaborations with the CDC and Oklahoma State University.
- First-mover advantage in developing perinatal-derived biologics for specific indications.
Acerca de OCEL
Organicell Regenerative Medicine, Inc., founded in 2011 and headquartered in Miami, Florida, is a clinical-stage biopharmaceutical company dedicated to the development of biological therapeutics for treating degenerative diseases. Originally incorporated as Biotech Products Services and Research, Inc., the company rebranded to Organicell Regenerative Medicine, Inc. in June 2018 to better reflect its focus on regenerative medicine. The company's primary product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources. Zofin is manufactured to retain naturally occurring microRNAs without any additives or diluents. Currently, Zofin is undergoing Phase I/II clinical trials as a potential treatment for COVID-19. Beyond its therapeutic development, Organicell also provides education, advertising, and marketing services to medical, healthcare, anti-aging, and regenerative service providers. The company has established research collaborations, including an agreement with the Centers for Disease Control and Prevention (CDC) to investigate Zofin's anti-inflammatory and anti-infective properties in influenza models and an agreement with Oklahoma State University to assess Zofin's efficacy in treating respiratory diseases caused by viruses with pandemic potential.
Qué hacen
- Develop biological therapeutics for degenerative diseases.
- Focus on acellular, biologic therapeutics derived from perinatal sources.
- Manufacture Zofin, a therapeutic retaining naturally occurring microRNAs.
- Conduct Phase I/II clinical trials for Zofin to treat COVID-19.
- Provide education, advertising, and marketing services to medical and healthcare providers.
- Collaborate with the CDC to study Zofin's effectiveness against influenza.
- Partner with Oklahoma State University to evaluate Zofin for respiratory diseases.
Modelo de Negocio
- Develop and commercialize biological therapeutics for degenerative diseases.
- Generate revenue through potential sales of Zofin, pending regulatory approval.
- Provide education, advertising, and marketing services to healthcare providers.
- Seek research and development funding through grants and partnerships.
Contexto de la Industria
Organicell operates within the competitive biotechnology industry, focusing on regenerative medicine. The market for regenerative medicine is projected to experience substantial growth, driven by increasing demand for therapies addressing degenerative diseases and aging-related conditions. Companies like AMHV, ATHJF, EMMLF, GRAMF, and KMSTF also operate in this space, developing various regenerative therapies. Organicell's focus on perinatal-derived biologics differentiates it within the market. The industry is characterized by high research and development costs, stringent regulatory requirements, and a lengthy time-to-market for new therapies.
Clientes Clave
- Patients suffering from degenerative diseases, including COVID-19.
- Medical and healthcare providers seeking regenerative medicine solutions.
- Research institutions and government agencies interested in biological therapeutics.
Finanzas
Gráfico e información
Precio de la acción de Organicell Regenerative Medicine, Inc. (OCEL): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para OCEL.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para OCEL.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para OCEL.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de OCEL en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Harry L. Leider FACPE,
CEO
Harry L. Leider brings extensive experience in healthcare management and leadership to Organicell. His background includes serving in executive roles at various healthcare organizations, focusing on strategic planning, operational efficiency, and business development. He is a Fellow of the American College of Physician Executives (FACPE), demonstrating his commitment to professional excellence in healthcare leadership. Leider's expertise encompasses areas such as healthcare delivery, managed care, and pharmaceutical services.
Historial: Under Harry L. Leider's leadership, Organicell has focused on advancing the clinical development of Zofin and establishing strategic partnerships. Key milestones include initiating Phase I/II clinical trials for COVID-19 and securing research agreements with the CDC and Oklahoma State University. Leider has also overseen the company's efforts to expand its intellectual property portfolio and explore new therapeutic applications for its biologic therapeutics.
Información del mercado OTC de OCEL
The OTC Other tier represents the lowest tier of the OTC market, indicating that Organicell Regenerative Medicine, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to strict listing standards, potentially increasing investment risk.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight compared to exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory issues involving the company.
- Review the company's investor relations materials and press releases.
- Consult with a financial advisor before investing.
- Phase I/II clinical trials for Zofin.
- Research agreements with the CDC and Oklahoma State University.
- CEO with experience in healthcare management.
- Focus on developing biological therapeutics for degenerative diseases.
Lo Que los Inversores Preguntan Sobre Organicell Regenerative Medicine, Inc. (OCEL)
¿Cuáles son los factores clave para evaluar OCEL?
Organicell Regenerative Medicine, Inc. (OCEL) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Proprietary technology in perinatal-derived biologics.. Riesgo principal a monitorear: Potential: Failure of Zofin in clinical trials.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de OCEL?
OCEL actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de OCEL?
Los precios de OCEL se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre OCEL?
La cobertura de analistas para OCEL incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en OCEL?
Las categorías de riesgo para OCEL incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure of Zofin in clinical trials.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de OCEL?
La relación P/E para OCEL compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está OCEL sobrevalorada o infravalorada?
Determinar si Organicell Regenerative Medicine, Inc. (OCEL) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de OCEL?
Organicell Regenerative Medicine, Inc. (OCEL) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for OCEL.